Page 2 - Clinical Program Updates News Today

Clinical updates on track for NKX101 in second quarter of 2023 at a company-hosted event and NKX019 in second half of 2023Cash and cash equivalents of...

Recognized standard clinical outcome assessment. In March: Tiziana announced a publication in the preeminent1 journal, Proceedings of the National Academy of Sciences , that... | April 26, 2023

NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel

Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy ultra-rare disease program - FDA... | January 31, 2023

– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across NSCLC, RCC and HCC – – Data support continued evaluation of SRF388... | May 26, 2022

-- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

(2022-05-05 | NDAQ:GRTS) Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

Fusion Pharmaceuticals Announces Fourth Quarter 2021 Financial Results and Clinical Program Updates - Company is advancing first targeted... | March 17, 2022

Press release content from Business Wire. The AP news staff was not involved in its creation. IMV Inc. Announces Fourth Quarter and Full Year 2020 Financial and Operational Results March 17, 2021 GMT DARTMOUTH, Nova Scotia--(BUSINESS WIRE)--Mar 17, 2021-- IMV Inc. (the “Company” or “IMV”) (TSX: IMV; NASDAQ: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies, today announced its financial and operational results for the fourth quarter and year en...